3,566 Shares in 10x Genomics, Inc. (NASDAQ:TXG) Purchased by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of 10x Genomics, Inc. (NASDAQ:TXG) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 3,566 shares of the company’s stock, valued at approximately $52,000.

A number of other institutional investors have also added to or reduced their stakes in the business. JPMorgan Chase & Co. lifted its position in shares of 10x Genomics by 355.0% during the third quarter. JPMorgan Chase & Co. now owns 355,488 shares of the company’s stock valued at $8,027,000 after buying an additional 277,355 shares during the last quarter. Lecap Asset Management Ltd. bought a new position in shares of 10x Genomics during the 3rd quarter worth approximately $877,000. Geode Capital Management LLC lifted its position in 10x Genomics by 2.4% during the third quarter. Geode Capital Management LLC now owns 1,815,710 shares of the company’s stock valued at $41,009,000 after acquiring an additional 42,777 shares during the last quarter. SG Americas Securities LLC boosted its stake in 10x Genomics by 209.8% in the fourth quarter. SG Americas Securities LLC now owns 73,046 shares of the company’s stock valued at $1,049,000 after acquiring an additional 49,468 shares in the last quarter. Finally, Point72 Asset Management L.P. purchased a new position in 10x Genomics in the third quarter worth $27,778,000. Hedge funds and other institutional investors own 84.68% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently commented on TXG. Leerink Partners lowered 10x Genomics from an “outperform” rating to a “market perform” rating and decreased their price objective for the company from $25.00 to $12.00 in a report on Thursday. JPMorgan Chase & Co. decreased their price target on 10x Genomics from $14.00 to $12.00 and set a “neutral” rating for the company in a research note on Thursday. Leerink Partnrs lowered 10x Genomics from a “strong-buy” rating to a “hold” rating in a research note on Thursday. The Goldman Sachs Group decreased their price objective on shares of 10x Genomics from $16.00 to $14.00 and set a “sell” rating for the company in a research report on Wednesday, October 30th. Finally, Morgan Stanley dropped their target price on shares of 10x Genomics from $28.00 to $26.00 and set an “overweight” rating on the stock in a research report on Friday. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $20.57.

10x Genomics Stock Up 3.1 %

Shares of NASDAQ:TXG opened at $12.31 on Friday. 10x Genomics, Inc. has a 52-week low of $10.80 and a 52-week high of $51.22. The stock has a market cap of $1.49 billion, a P/E ratio of -8.05 and a beta of 1.85. The business has a fifty day moving average of $14.68 and a two-hundred day moving average of $17.37.

10x Genomics (NASDAQ:TXG) last announced its quarterly earnings data on Wednesday, February 12th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.08). 10x Genomics had a negative net margin of 28.93% and a negative return on equity of 25.07%. On average, equities analysts anticipate that 10x Genomics, Inc. will post -1.43 earnings per share for the current year.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.